GenMark Diagnostics (GNMK) Stock Price, News & Analysis

Company Overview

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $24.04 to $24.04
• 50-Day Range: $23.89 to $24.04
• 52-Week Range: $8.42 to $24.25
• Volume: N/A
• Average Volume: 2.70 million shs
• Market Capitalization: $1.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNMK Stock Analysis - Frequently Asked Questions

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc. (NASDAQ:GNMK) announced its quarterly earnings results on Thursday, February, 25th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The medical equipment provider earned $50.08 million during the quarter, compared to analyst estimates of $50 million. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%.

What other stocks do shareholders of GenMark Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GenMark Diagnostics investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Enphase Energy (ENPH) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 2/25/2021
• Today: 12/25/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GNMK
• CUSIP: N/A
• CIK: 1487371
• Web: www.genmarkdx.com
• Phone: 760-448-4300
• Fax: N/A
• Employees: 618
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,350,000.00
• Net Margins: -16.95%
• Pretax Margin: N/A
• Return on Equity: -39.36%
• Return on Assets: -13.02%

Debt

• Debt-to-Equity Ratio: 0.75
• Current Ratio: 4.33
• Quick Ratio: 3.84

Sales & Book Value

• Annual Sales: $88.02 million
• Price / Sales: 19.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 114.48

Miscellaneous

• Outstanding Shares: 73,086,000
• Free Float: N/A
• Market Cap: $1.76 billion
• Optionable: Optionable
• Beta: 3.02